We are pleased to announce the awardees of the John M. Eisenberg Memorial Lectureship on Therapeutics Research conducted by each of the seven CERT centers over the next 12 months. The Eisenberg Lectureship is supported through an unrestricted educational grant from Pfizer, Inc. This is a joint project sponsored internally by U.S. Medical in partnership with Outcomes Research and the Public Health Group.
Following is a list of the lectureship awarded this year:
RECIPIENT INSTITUTION: Medical University of South Carolina
Charleston, South Carolina
SPEAKER: Robert Califf (Duke CERTs)
TOPIC: Cardiovascular Therapeutics Research.
RECIPIENT INSTITUTION: University of Colorado Health Sciences Center
SPEAKERS: Daniel Malone, Marietta Anthony, Lane Johnson (Arizona CERTs)
TOPICS: Drug-Drug Interactions; Pharmacokinetics and Pharmacodynamic Differences Between Men and Women; Herbal Products.
RECIPIENT INSTITUTION: Morehouse School of Medicine
SPEAKERS: Jeroan Allison, Kenneth Saag, Norman Weissman (UAB CERTs)
TOPICS: Patient Preferences and Provider Practices in Osteoporosis; Racial and Ethnic Disparities in Musculoskeletal Disorders; Improving Quality of Care: Focus on Translating Research into Practice.
RECIPIENT INSTITUTION: Creighton University Medical Center
SPEAKERS: William Campbell, Rowell Daniels, Diane Cousins (UNC CERTs)
TOPICS: The Interface of Pharmaceutical Care, Therapeutics and Patient Safety.
RECIPIENT INSTITUTION: Indiana University School of Medicine
SPEAKER: Richard Platt (HMO Research Network CERTs)
TOPICS: CERTs: The Relevance of Pharmacoepidemiologic Research; Bringing Together an Infrastructure for Pharmacoepidemiologic Research; Education and Research Training Opportunities in Pharmacoepidemiology.
RECIPIENT INSTITUTION: University of California
San Francisco, California
SPEAKER: Brian Strom (Penn CERTs)
TOPICS: Challenges in the Identification of Adverse Reactions to Herbs and Drugs.
RECIPIENT INSTITUTION: Baylor College of Medicine
SPEAKERS: Wayne Ray, Walter Smalley (Vanderbilt CERTs)
TOPIC: Ensuring the Safe use of Drugs: The Limitation of Current Policies; Use of Administrative Data for Postmarketing drug-safety research.